Article,
Fatigue predicts quality of life after leucine‐rich glioma‐inactivated 1‐antibody encephalitis
Contributors
Binks, Sophie N M
0000-0003-0991-5998
[1]
[2]
Veldsman, Michele
0000-0003-2192-378X
[1]
Handel, Adam E
0000-0001-8385-6346
[1]
[2]
Jacob, Saiju
0000-0003-0037-454X
[3]
Coebergh, Jan Adriaan F
0000-0002-2419-3930
[5]
Ramanathan, Sudarshini
0000-0002-0294-9768
[1]
[6]
[7]
Easton, Ava
0000-0002-1739-2915
[8]
[9]
Nissen, Mette Scheller
0000-0002-3512-3479
[10]
[11]
Leite, Maria Isabel Silva
0000-0002-4277-9855
[1]
[2]
Okai, David
0000-0002-0298-2031
[12]
Blaabjerg, Morten
0000-0001-6007-1861
[10]
[11]
Husain, Masud
0000-0002-6850-9255
[1]
Irani, Sarosh R
0000-0002-7667-9748
(Corresponding author)
[1]
[2]
[13]
Affiliations
- [1] University of Oxford [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [2] Oxford University Hospitals NHS Trust [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [3] Queen Elizabeth Hospital Birmingham [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [4] Queen's Medical Centre [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [5] St Peter's Hospital [NORA names: United Kingdom; Europe, Non-EU; OECD];
(... more)
Abstract
Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.
